Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study
NCT ID: NCT07145281
Last Updated: 2025-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2022-11-10
2024-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does sublingual estradiol reduce free Protein S levels compared to oral estradiol with cyproterone acetate?
Does sublingual estradiol accelerate activation of the clotting system, as measured by thrombin generation?
Researchers will compare sublingual estradiol to oral estradiol plus cyproterone acetate to see if the way estradiol is taken changes blood clotting risk.
Participants will:
Take either sublingual estradiol (2 mg daily in divided doses) or oral estradiol (2 mg daily) with cyproterone acetate (10 mg daily) for 6 months
Provide blood samples at baseline and after 6 months to measure hormone levels and clotting factors
Attend clinic visits for monitoring, including safety checks and routine laboratory tests
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients
NCT05428215
Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome
NCT06570460
Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
NCT01023178
Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users
NCT06067217
Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers
NCT02245438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sublingual Estradiol
Participants receive sublingual estradiol 2 mg per day divided into 4 doses, without an anti-androgen, for 6 months.
Estradiol (E2)
Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).
In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.
All participants are treatment-naive.
Oral Estradiol + Cyproterone Acetate (CPA)
Participants receive oral estradiol 2 mg once daily combined with cyproterone acetate 10 mg once daily for 6 months. This represents the standard regimen used in routine care.
Estradiol (E2)
Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).
In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.
All participants are treatment-naive.
Cyproterone Acetate (Androcur, BAY94-8367)
Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.
All participants are treatment-naive.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estradiol (E2)
Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).
In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.
All participants are treatment-naive.
Cyproterone Acetate (Androcur, BAY94-8367)
Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.
All participants are treatment-naive.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 to 45 years
* Healthy individuals
* Treatment-naïve (not previously exposed to gender-affirming hormone therapy)
* Presenting for gender-affirming hormone therapy (GAHT)
* Provided written informed consent
Exclusion Criteria
* Personal or family history of venous thromboembolism (VTE) or thrombophilia
* History of malignancy in the past 5 years
* Chronic liver disease
* Chronic kidney disease
* Hyperlipidemia
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shmuel Kivity, MD
IRB Head
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iris Yaish, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv Sourasky Medical Center - Institute of Endocrinology, Metabolism and Hypertension
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658.
Dhejne C, Van Vlerken R, Heylens G, Arcelus J. Mental health and gender dysphoria: A review of the literature. Int Rev Psychiatry. 2016;28(1):44-57. doi: 10.3109/09540261.2015.1115753.
Ali-Saleh M, Sarig G, Ablin JN, Brenner B, Jacob G. Inhalation of a Short-Acting beta2-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects. PLoS One. 2016 Jul 5;11(7):e0158652. doi: 10.1371/journal.pone.0158652. eCollection 2016.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Association; 2013.
Even Zohar N, Sofer Y, Yaish I, Serebro M, Tordjman K, Greenman Y. Low-Dose Cyproterone Acetate Treatment for Transgender Women. J Sex Med. 2021 Jul;18(7):1292-1298. doi: 10.1016/j.jsxm.2021.04.008. Epub 2021 Jun 24.
Connors JM, Middeldorp S. Transgender patients and the role of the coagulation clinician. J Thromb Haemost. 2019 Nov;17(11):1790-1797. doi: 10.1111/jth.14626. Epub 2019 Sep 13.
Dupuis M, Severin S, Noirrit-Esclassan E, Arnal JF, Payrastre B, Valera MC. Effects of Estrogens on Platelets and Megakaryocytes. Int J Mol Sci. 2019 Jun 25;20(12):3111. doi: 10.3390/ijms20123111.
Yokota N, Inoue R, Kawamura K, Egashira K, Kuma H, Kato K. The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients. Eur J Obstet Gynecol Reprod Biol. 2024 Apr;295:67-74. doi: 10.1016/j.ejogrb.2024.01.028. Epub 2024 Jan 29.
Mihaila RG, Catana C, Olteanu AL, Birlutiu V, Salcudean C, Mihaila MD. Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. Biomarkers. 2019 Jun;24(4):389-393. doi: 10.1080/1354750X.2019.1600021. Epub 2019 Apr 9.
Volod O, Runge A. The TEG 5000 System: System Description and Protocol for Measurements. Methods Mol Biol. 2023;2663:725-733. doi: 10.1007/978-1-0716-3175-1_48.
Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9. doi: 10.1210/jc.2003-030520.
van Ommen CH, Fijnvandraat K, Vulsma T, Delemarre-Van De Waal HA, Peters M. Acquired protein S deficiency caused by estrogen treatment of tall stature. J Pediatr. 1999 Oct;135(4):477-81. doi: 10.1016/s0022-3476(99)70171-x.
Raps M, Helmerhorst FM, Fleischer K, Dahm AE, Rosendaal FR, Rosing J, Reitsma P, Sandset PM, van Vliet HA. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost. 2013 Apr;109(4):606-13. doi: 10.1160/TH12-10-0771. Epub 2013 Feb 14.
Majumder R, Nguyen T. Protein S: function, regulation, and clinical perspectives. Curr Opin Hematol. 2021 Sep 1;28(5):339-344. doi: 10.1097/MOH.0000000000000663.
Bogehave M, Glintborg D, Christensen LL, T'Sjoen G, Vervalcke J, Wiepjes CM, den Heijer M, Andersen MS, Bladbjerg EM. The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen. J Thromb Haemost. 2025 Oct;23(10):3084-3097. doi: 10.1016/j.jtha.2025.03.006. Epub 2025 Mar 14.
Lim HY, Leemaqz SY, Torkamani N, Grossmann M, Zajac JD, Nandurkar H, Ho P, Cheung AS. Global Coagulation Assays in Transgender Women on Oral and Transdermal Estradiol Therapy. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa262. doi: 10.1210/clinem/dgaa262.
Scheres LJJ, Selier NLD, Nota NM, van Diemen JJK, Cannegieter SC, den Heijer M. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost. 2021 Apr;19(4):1029-1037. doi: 10.1111/jth.15256. Epub 2021 Feb 22.
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989 Sep;38(9):869-73. doi: 10.1016/0026-0495(89)90233-3.
Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation. 2019 Mar 12;139(11):1461-1462. doi: 10.1161/CIRCULATIONAHA.118.038584. No abstract available.
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017 Apr;5(4):291-300. doi: 10.1016/S2213-8587(16)30319-9. Epub 2016 Dec 2.
Eisenberger A, Westhoff C. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol. 2014 Jul;142:76-82. doi: 10.1016/j.jsbmb.2013.08.016. Epub 2013 Sep 3.
Doll E, Gunsolus I, Thorgerson A, Tangpricha V, Lamberton N, Sarvaideo JL. Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women. Endocr Pract. 2022 Mar;28(3):237-242. doi: 10.1016/j.eprac.2021.11.081. Epub 2021 Nov 13.
Angus LM, Nolan BJ, Zajac JD, Cheung AS. A systematic review of antiandrogens and feminization in transgender women. Clin Endocrinol (Oxf). 2021 May;94(5):743-752. doi: 10.1111/cen.14329. Epub 2020 Oct 5.
Haupt C, Henke M, Kutschmar A, Hauser B, Baldinger S, Saenz SR, Schreiber G. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. Cochrane Database Syst Rev. 2020 Nov 28;11(11):CD013138. doi: 10.1002/14651858.CD013138.pub2.
Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015 Nov;82(3):304-7. doi: 10.1016/j.maturitas.2015.06.040. Epub 2015 Jul 26.
Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):149-64. doi: 10.1016/s1521-690x(02)00079-9.
Yaish I, Gindis G, Greenman Y, Moshe Y, Arbiv M, Buch A, Sofer Y, Shefer G, Tordjman K. Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study. Transgend Health. 2023 Dec 13;8(6):485-493. doi: 10.1089/trgh.2023.0022. eCollection 2023 Dec.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
View DocumentOther Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOH_2022-10-11_012120
Identifier Type: OTHER
Identifier Source: secondary_id
0388-22-TLV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.